Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

NRAS wild-type

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

Related tests:

FoundationOne® CDx (110)

MI Cancer Seek™

FoundationOne® CDx (110)

MI Cancer Seek™

NRAS wild-type	Rectal Cancer	NRAS wild-type	Rectal Cancer	panitumumab Sensitive: A2 - Guideline panitumumab Sensitive : A2	panitumumab Sensitive: A2 - Guideline panitumumab Sensitive : A2
NRAS wild-type	Colon Cancer	NRAS wild-type	Colon Cancer	panitumumab Sensitive: A2 - Guideline panitumumab Sensitive : A2	panitumumab Sensitive: A2 - Guideline panitumumab Sensitive : A2
NRAS wild-type	Colon Cancer	NRAS wild-type	Colon Cancer	cetuximab Sensitive: A2 - Guideline cetuximab Sensitive : A2	cetuximab Sensitive: A2 - Guideline cetuximab Sensitive : A2
NRAS wild-type	Rectal Cancer	NRAS wild-type	Rectal Cancer	cetuximab Sensitive: A2 - Guideline cetuximab Sensitive : A2	cetuximab Sensitive: A2 - Guideline cetuximab Sensitive : A2
NRAS wild-type	Colorectal Cancer	NRAS wild-type	Colorectal Cancer	panitumumab Sensitive: C2 – Inclusion Criteria panitumumab Sensitive : C2	panitumumab Sensitive: C2 – Inclusion Criteria panitumumab Sensitive : C2
NRAS wild-type	Colorectal Cancer	NRAS wild-type	Colorectal Cancer	CPGJ-602 Sensitive: C2 – Inclusion Criteria CPGJ-602 Sensitive : C2	CPGJ-602 Sensitive: C2 – Inclusion Criteria CPGJ-602 Sensitive : C2
NRAS wild-type	Colorectal Cancer	NRAS wild-type	Colorectal Cancer	cetuximab Resistant: C3 – Early Trials cetuximab Resistant : C3	cetuximab Resistant: C3 – Early Trials cetuximab Resistant : C3
NRAS wild-type	Colorectal Cancer	NRAS wild-type	Colorectal Cancer	SCT200 Sensitive: C3 – Early Trials SCT200 Sensitive : C3	SCT200 Sensitive: C3 – Early Trials SCT200 Sensitive : C3
NRAS wild-type	Melanoma	NRAS wild-type	Melanoma	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3
NRAS wild-type	Glioblastoma	NRAS wild-type	Glioblastoma	panitumumab Sensitive: C3 – Early Trials panitumumab Sensitive : C3	panitumumab Sensitive: C3 – Early Trials panitumumab Sensitive : C3